Published: 22.11.2017 12:00

Osteoporosis trials

«Osteoporosis trials» in pictures.

Osteoporosis Clinical Trial Design: Regulatory History

Affiliations Department of Medicine, Duke University School of Medicine, Durham, North Carolina, United States of America, Department of Medicine, Durham Veterans Affairs Medical Center, Durham, North Carolina, United States of America, Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, United States of America

Clinical Trials in Osteoporosis | Derek Pearson | Springer

Osteoporosis, which means porous bone, is a disease in which the bones gradually become weak and brittle. The condition often results in broken bones, or fractures, especially of the hip, wrist, and spine, even from simple activities like lifting a chair or bending over. According to the National Institutes of Health (NIH), about 89 million Americans have osteoporosis. Another 68 million have low bone mass and are at an increased risk for the disease. Osteoporosis is common among the elderly, but the disease can strike at any age. Although it is more common in older women, men can also develop osteoporosis. One of every 7 women and 6 in every 9 men older than 55 years of age will have an osteoporosis-related fracture in their lifetime.

Clinical trials - Osteoporosis - Mayo Clinic

Zhang Y, Chen WF, Lai WP, Wong MS. Soy isoflavones and their bone protective effects. Inflammopharmacology. 7558 Sep 76.

We have completed our pilot study and found that transdermal nitroglycerin was associated with fewer headaches than oral isosorbide mononitrate. We are currently recruiting patients for our second main study.

Vitamin D: In order to absorb enough calcium, your body also needs vitamin D. The National Osteoporosis Foundation recommends the following:

Percent change in lumbar spine BMD in ovariectomized rats after 67 weeks of treatment with nitroglycerin (NTG) ointment 79.

Conceived and designed the experiments: KB JBG BCB WCL AT KC. Performed the experiments: KB JBG BCB WCL. Analyzed the data: AT KC. Wrote the paper: KB JBG BCB WCL KC. Data interpretation: KB JBG BCB WCL KC.

Competing interests: The authors have read the journal's policy and have the following competing interests: WCL has received grants from Amarin, Janssen, Regeneron, and Sanofi-Aventis outside the submitted work. JBG has received grants from AstraZeneca, Janssen, GlaxoSmithKline, Medtronic, grants and personal fees from Merck, and non-financial consulting for Integrity CE, PriMed CE, and the Endocrine Society outside the submitted work. The other authors report that they have no competing interests. This does not alter the authors' adherence to PLOS One policies on sharing data and materials.

The experimental drug, romosozumab, frees the body's ability to stimulate bone production by blocking biochemical signals that naturally inhibit bone formation, explained Dr. Michael McClung, founding director of the Oregon Osteoporosis Center in Portland, Ore.

* Based on a t-test, assuming a two sided alpha of a power of and a standard deviation of change in BMD measurements of %.